---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000300"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:56:34.105622+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio expands OPKO pact to include oral LA-PTH; appoints OPKO exec Rubin to board

## Summary
- Expanded collaboration covers once-daily oral LA-PTH tablet for hypoparathyroidism; 50/50 cost sharing.
- IND filing for LA-PTH expected late 2026 after positive PK/PD data in December 2025.
- Gerry Ostrov resigned as director effective Feb 1, 2026; Steven Rubin appointed as Class III director.
- Rubin also chairs audit committee and serves on compensation committee; he is EVP at OPKO.
- Oral OXM program progressing; Phase 1 injectable OXM data expected late 2026.

## SEC filing metadata
- accession: 0001178913-26-000300
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/0001178913-26-000300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/zk2634279.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000300
- JSON: https://secwatch.observer/filing/0001178913-26-000300.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000300.txt

## Key facts
- Material Agreements
  Entera Bio Ltd. amended Amended and Restated Collaboration and License Agreement with OPKO Health, Inc. and OPKO Biologics Ltd. (effective 2026-02-03).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: OPKO Health, Inc. and OPKO Biologics Ltd.
  - Effective: 2026-02-03
  source text: On February 3, 2026, the Company and OPKO entered into an amended and restated collaboration and license agreement (the “ A&R Collaboration Agreement ”), which amends and restates the Original Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect to the preclinical and clinical development of a daily long acting PTH tablet (“ LA-PTH ”) for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide program .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/0001178913-26-000300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.